AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PepGen's Promising Clinical Milestones and Strategic Advancements Earn a Buy Rating
ByAinvest
Friday, Aug 8, 2025 12:07 pm ET1min read
Analyst Ananda Ghosh of H.C. Wainwright maintains a Buy rating on PepGen Inc. with a price target of $8.00, citing the completion of dosing in the FREEDOM-DM1 trial's 15 mg/kg cohort and robust splicing correction at lower doses. The safety profile of PepGen's EDO platform and potential for acquisition interest in the growing DM1 market also contribute to the positive outlook. Ghosh has a 3-star analyst rating with an average return of 8.8% and a 55.56% success rate.
PepGen Inc. (PEPG), a clinical-stage biotechnology company, recently reported its second-quarter 2025 financial results and corporate highlights. The company, which focuses on developing next-generation oligonucleotide therapies for severe neuromuscular and neurological disorders, provided updates on its myotonic dystrophy type 1 (DM1) program and financial performance.Clinical Progress
The company completed patient dosing in the 15 mg/kg cohort of the FREEDOM trial for PGN-EDODM1, with topline data expected in early Q4 2025. Based on positive splicing correction results and safety data, PepGen will conclude the FREEDOM trial at the 15 mg/kg dose level and transition to FREEDOM2, its Phase 2 multiple ascending dose study. The company expects to report results from the 5 mg/kg cohort of FREEDOM2 in Q1 2026 [1].
Financial Performance
Financial highlights include $74.7 million in cash and equivalents as of June 30, 2025, with runway into Q2 2026. The company reported a net loss of $23.1 million, or $(0.70) per share, for Q2 2025, compared to $28.3 million in Q2 2024 [1].
Analyst Perspective
Analyst Ananda Ghosh of H.C. Wainwright maintains a Buy rating on PepGen Inc. with a price target of $8.00. Ghosh cited the completion of dosing in the FREEDOM-DM1 trial's 15 mg/kg cohort and robust splicing correction at lower doses. The safety profile of PepGen's EDO platform and potential for acquisition interest in the growing DM1 market also contribute to the positive outlook [2].
References
[1] https://www.stocktitan.net/news/PEPG/
[2] https://www.stocktitan.net/news/PEPG/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet